I understand Biota has a world (ex USA) patent until 2011, with the USA patent until 2014.
These Indian companies are substantial entities and I am sure will honour any royalties/patents due, they would not risk their current business by producing without licence.
It is also my understanding that GSK cannot licence to a third party without Biota's approval, therefore the current 7% royalty could be lower or higher depending on what Biota agree to.
It is obviously in Biota's interests to agree to third party licencing as it is more royalty $ to them, but very importantly one would expect GSK will have to be more open with Biota regarding current orders if the dialogue for Biota's approval was to occur. It may also bring forward a potential settlement.
- Forums
- ASX - By Stock
- BTA
- question re patents
question re patents, page-3
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online